Taimei Medical Technology Strengthens Industry Leadership Through Deep Integration of Cutting-Edge Technology and Innovative Digital Platforms

As the pharmaceutical and medical device industries continue to pursue greater innovation efficiency and quality, digital and intelligent technologies are being increasingly deeply integrated into these sectors, attracting a multitude of high-quality enterprises. On the evening of September 16, Zhejiang Taimei Medical Technology Co., Ltd. passed the hearing by the Hong Kong Stock Exchange and is expected to launch its initial public offering in the near future. As the only domestic provider capable of delivering one-stop digital solutions spanning from research and development to marketing for the pharmaceutical and medical device industries, Taimei Medical Technology is helping to drive the sector’s sustained, high-quality development.

Founded in 2013, Taimei Medical Technology is a China-based provider of digital solutions dedicated to the pharmaceutical and medical device industries. It primarily designs and delivers industry-specific software and digital services to accelerate the research and development (R&D) and marketing of innovative drugs, medical devices, and other products. According to Frost & Sullivan, Taimei Medical Technology was the largest digital solutions provider in China’s pharmaceutical and medical device R&D and marketing sector by revenue in 2023.

A robust digital platform serves as the core of Taimei Medical Technology’s rapid technological iteration and innovation, providing strong support for its comprehensive product portfolio. The company’s two major digital collaboration platforms, TrialOS and PharmaOS, act as hubs connecting all stakeholders across the pharmaceutical and medical device industry chains, spanning from pharmaceutical and medical device companies and hospitals to third-party service providers, patients, and regulatory authorities. These platforms integrate critical data and break down barriers among industry participants through effective data exchange and optimized, coordinated workflows. This facilitates seamless online collaboration among R&D and marketing partners, not only ensuring high customer loyalty but also creating cross-selling opportunities for enterprises.

Meanwhile, Taimei Medical Technology boasts a comprehensive product portfolio capable of meeting the needs of diverse consumer segments. As of March 31, 2024, the company offered more than 40 software products and digital services, catering to various organizations and roles within the pharmaceutical and medical device industries. These offerings cover multiple scenarios, including trial design and management, patient recruitment and follow-up, data collection and analysis, remote monitoring, and sales relationship management. By seamlessly integrating digital services and software on its platform, the company provides efficient, high-quality one-stop solutions that streamline life science R&D and marketing processes, thereby enhancing efficiency and improving quality. According to Frost & Sullivan, Taimei Medical Technology is the only provider in China capable of delivering end-to-end digital solutions—from R&D to marketing—for the life sciences industry.

Robust technological and data capabilities are one of the key factors behind the success of Taimei Medical Technology. Its advanced technical strength not only enables the company to rapidly respond to and identify anomalies, delivering more personalized products and services to users, but also allows it to maintain a leading edge in research and development and innovation, thereby securing a competitive advantage in a highly contested market.

Since its establishment, Taimei Medical Technology has prioritized research and development (R&D), continuously investing in advanced technologies to drive product development and enhance service quality. As of March 31, 2024, the company had assembled a robust R&D team comprising 186 members. Furthermore, as of the Latest Practicable Date, it held 220 issued patents in China, including 112 invention patents.

Meanwhile, Taimei Medical Technology has applied AI to streamline and enhance various aspects of clinical research and management, leveraging advanced algorithms and models for data processing, feature engineering, and the development and deployment of AI-driven solutions, ultimately improving efficiency and accuracy in the pharmaceutical and medical device industries. Furthermore, Taimei Medical Technology has developed big data platform technologies for the pharmaceutical and medical device sectors to handle complex clinical data. This big data technology supports near real-time analysis of highly customized data structures and complex associations encountered in clinical research and pharmacovigilance.

Benefiting from advanced data analytics tools and a comprehensive product portfolio, Taimei Medical Technology has established a high-quality, loyal customer base in recent years, encompassing renowned multinational pharmaceutical companies and domestic industry leaders, as well as emerging innovative pharmaceutical enterprises and mainstream CROs and other third-party service providers. As of March 31, 2024, the Company had provided services to more than 1,400 pharmaceutical companies and CROs, covering 21 of the top 25 global pharmaceutical companies and 90 of the Top 100 Innovative Pharmaceutical Companies in China.

According to Frost & Sullivan data, as of 2023, Taimei Medical Technology was the most widely adopted provider of digital solutions in the research and development and marketing sectors of China’s pharmaceutical and medical device industries, measured by customer count. As of March 31, 2024, the Company had provided services to more than 1,400 pharmaceutical companies and contracted research organizations, and had established partnerships with over 700 National Drug Clinical Trial Institutions, more than 80% of which were Grade A tertiary hospitals. The Company’s customer base grew from 908 in 2021 to 1,033 in 2022, and further increased to 1,107 in 2023.

A large and loyal customer base not only enables the company to consolidate its industry position, thereby enhancing its influence and voice in the market, but also helps attract new customers and increase market share through positive word-of-mouth effects, thus ensuring a stable revenue stream for the company.

The prospectus shows: In terms of financials, Taimei Medical Technology's performance continued to grow during the track record period. Total revenue increased by 17.8% from RMB 466 million in 2021 to RMB 549 million in 2022, then further increased by 4.4% to RMB 573 million in 2023, maintaining an upward trend. Revenue for the three months ended March 31, 2023, was RMB 129 million, which increased by 2.2% to RMB 132 million for the three months ended March 31, 2024.

From an industry perspective, driven by increasing clinical demand and continuous advancements in R&D, China’s pharmaceutical and medical device R&D expenditure grew from RMB 139.8 billion in 2019 to RMB 261.2 billion in 2023, representing a compound annual growth rate (CAGR) of 16.9%. It is projected to further increase to RMB 512.3 billion by 2028, at a CAGR of 14.4%. Meanwhile, China’s pharmaceutical and medical device marketing expenditure rose from RMB 630.8 billion in 2019 to RMB 842.6 billion in 2023, with a CAGR of 7.5%, and is expected to grow further to RMB 1.1058 trillion by 2028, at a CAGR of 5.6%. The future growth potential is substantial.

Facing immense growth potential and opportunities, Taimei Medical Technology, as an early and key market participant in digital solutions for the pharmaceutical and medical device industries, will continue to leverage its unique and specialized digital platform, robust technological and data capabilities, and large, loyal base of high-quality customers. The company will steadily increase R&D investment, continuously update and expand its products and services, and fully capitalize on its first-mover advantage and technical expertise to pursue international expansion, consolidate market share, strengthen its industry position, and support the long-term, stable growth of its business.